Bluebird marks progress on Lentiglobin gene therapy – BioPharma Dive
Thorold News |
Bluebird marks progress on Lentiglobin gene therapy
BioPharma Dive New data on Bluebird Bio Inc.'s gene therapy for sickle cell disease suggest manufacturing changes made last fall are boosting the treatment's potency, although investors looking for more conclusive evidence of improvement will have to wait until later … bluebird bio Reports Third Quarter 2017 Financial Results and Recent Operational Progress bluebird bio to Present New Data from Clinical Studies of LentiGlobinTM Gene Therapy in Transfusion-Dependent β … bluebird bio (BLUE) Earns Daily Media Sentiment Score of 0.08 |
